Background Sodium glucose co-transporter 2 inhibitors (SGLT2i) are one of the
cornerstones of heart failure (HF) therapy. While benefits in terms of HF hospitalizations and …

Aim Persistent symptoms despite guideline‐directed medical therapy (GDMT) and poor
tolerance of GDMT are hallmarks of patients with advanced heart failure (HF) with reduced …

Aims The aim of this analysis was to provide data on the overall comorbidity burden, both
cardiovascular (CV) and non‐CV, in a large real‐world heart failure (HF) population across …

In the last years, major progress has occurred in heart failure (HF) management. The 2023
ESC focused update of the 2021 HF guidelines introduced new key recommendations …

Abstract Background Safety, Tolerability and Efficacy of Rapid Optimization, Helped by NT-
proBNP Testing, of Heart Failure Therapies (STRONG-HF) demonstrated the safety and …

Guideline‐directed medical therapy (GDMT) in patients with heart failure and reduced
ejection fraction (HFrEF) reduces morbidity and mortality, but its implementation is often poor …

Aims A high‐intensity care (HIC) strategy with rapid guideline‐directed medical therapy
(GDMT) up‐titration and close follow‐up visits improved outcomes, compared to usual care …

Patients with an established diagnosis of heart failure (HF) with reduced ejection fraction
(HFrEF) are prone to experience episodes of worsening symptoms and signs despite …

Background Hospitalization is associated with poor outcomes in patients with heart failure,
but its prognostic role in advanced heart failure is still unsettled. We evaluated the …

Background Patient education at the time of discharge is one of the most important
challenges in the emergency department. This study aimed to evaluate the Effect of …